Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression

Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression

As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of...

Full description

Bibliographic Details
Main Authors: Panxia Wang, Minghui Wang, Yuehuai Hu, Jianxing Chen, Yanjun Cao, Cui Liu, Zhongkai Wu, Juan Shen, Jing Lu, Peiqing Liu
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Isorhapontigenin
YAP1
Doxorubicin
Cardiotoxicity
Cardiomyocytes apoptosis
TEAD1
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383520307693

Internet

http://www.sciencedirect.com/science/article/pii/S2211383520307693

Similar Items